These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2946740)

  • 1. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty.
    Whitworth HB; Roubin GS; Hollman J; Meier B; Leimgruber PP; Douglas JS; King SB; Gruentzig AR
    J Am Coll Cardiol; 1986 Dec; 8(6):1271-6. PubMed ID: 2946740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective effect of intracoronary nifedipine during percutaneous transluminal coronary angioplasty. A French double-blind cross-over multicentre study.
    Juillière Y; Danchin N; Bertrand ME; Bassand JP; Bory M; Bigonzi F; Grolleau R; Lablanche JM; Barragan P; Gaspard P
    Int J Cardiol; 1993 Apr; 39(1):43-8. PubMed ID: 8407006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
    N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
    Hoberg E; Dietz R; Frees U; Katus HA; Rauch B; Schömig A; Schuler G; Schwarz F; Tillmanns H; Niebauer J
    Br Heart J; 1994 Mar; 71(3):254-60. PubMed ID: 8142195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Gibson CM; Goel M; Cohen DJ; Piana RN; Deckelbaum LI; Harris KE; King SB
    J Am Coll Cardiol; 1998 Jul; 32(1):28-34. PubMed ID: 9669245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary artery spasm at the site of angioplasty in the first 2 months after successful percutaneous transluminal coronary angioplasty.
    Hollman J; Austin GE; Gruentzig AR; Douglas JS; King SB
    J Am Coll Cardiol; 1983 Dec; 2(6):1039-45. PubMed ID: 6226727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous transluminal coronary angioplasty in patients with spasm superimposed on atherosclerotic narrowing.
    Bertrand ME; Lablanche JM; Fourrier JL; Traisnel G
    Br Heart J; 1987 Nov; 58(5):469-72. PubMed ID: 2960366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy.
    Leisch F; Herbinger W; Brücke P
    Clin Cardiol; 1984 Dec; 7(12):654-9. PubMed ID: 6239723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
    Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
    Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulotroban during and after coronary angioplasty. A double-blind, placebo controlled study.
    Finci L; Höfling B; Ludwig B; Bulitta M; Steffenino G; Etti H; Meier B
    Z Kardiol; 1989; 78 Suppl 3():50-4. PubMed ID: 2530714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
    Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
    Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial.
    Johansen O; Brekke M; Seljeflot I; Abdelnoor M; Arnesen H
    J Am Coll Cardiol; 1999 May; 33(6):1619-26. PubMed ID: 10334433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
    Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
    J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.